Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Recruiting 4Completed 3Active not recruiting 2Suspended 1Not yet recruiting 1

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 34Gastrointestinal 17Gynecologic 6Thoracic 5Tumor-Agnostic 4Genitourinary 3CNS 3Sarcoma 2Other solid neoplasm 2Head & Neck 2Dermatologic 2

Conditions

Neoplasm Metastasis 4

Interventions

pembrolizumab 26Specimen Handling 17Blood Specimen Collection 17Biopsy 16Magnetic Resonance Spectroscopy 15atezolizumab 11Surveys and Questionnaires 11Bevacizumab 9Radiotherapy 8Radiosurgery 8Nivolumab 8Fluorouracil 8Standard of Care 7Paclitaxel 7Irinotecan 7Gemcitabine 7Cisplatin 7olaparib 6durvalumab 6Palliative Care 6Oxaliplatin 6Leucovorin 6Cyclophosphamide 6Carboplatin 6Capecitabine 6alectinib 5abemaciclib 5Trastuzumab 5Interviews as Topic 5Exercise 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × trastuzumab deruxtecan × Tumor-Agnostic × Clear all
NCT04585958 2026-06-05

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting
55 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT07086768 2026-06-03

Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors

The University of Texas Health Science Center at San Antonio

Phase 1 Recruiting
57 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06311214 2026-05-27

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
500 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06174987 2025-10-15

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Daiichi Sankyo

Phase 3 Recruiting
50 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡